Skyline announces Chief Development Officer as it advances multiple innovative research programs towards clinical stage
January 01, 2022

Shanghai, January 01, 2022 – Skyline Therapeutics today announced the appointment of Dr. Ling Su as the Company’s Chief Development Officer, effective January 1, 2022. In this role, Dr. Su will lead Skyline’s drug development efforts.


Dr. Su brings three decades of experience in pharmaceutical regulatory and clinical development. He previously served as a senior executive at several multinational pharmaceutical companies, including Merck & Co., Roche, Wyeth and Novartis, building drug development organizations across China, and leading large global clinical trials and drug development programs in China and Asia. Earlier in his career, Dr. Su worked for China’s Bureau of Drugs at the Ministry of Health (the predecessor of today's NMPA), and at the Center for Drug Evaluation and Research (CDER) at the US Federal Drug Administration.


Skyline has established a diverse pipeline to address unmet needs across different therapeutic areas. With the Skyline team advancing various innovative research programs rapidly forward, from discovery and preclinical study phases towards clinical development, the rich experience and expert insights brough by Dr. Su is expected to provide valuable guidance and leadership in drug development and regulation for the new class of advanced therapies.